TP53

Live from ESMO 2023 | Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC

Retrieved on: 
Lunedì, Ottobre 23, 2023
TKI, Bone marrow, PRS, NSCLC, Notifiable disease, Mini, Aes, ESMO, TP53, QW, Hepatitis, Congress, PFS, European Society for Medical Oncology, CHB, Pharmacokinetics, Disease, Oncology, ORR, Safety, Cancer, Apoptosis, Patient, Prognosis, Cohort, EGFR, Pharmaceutical industry

The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.

Key Points: 
  • The clinical data presented at the ESMO Congress this year demonstrated promising therapeutic utility of pelcitoclax combined with osimertinib in patients with EGFR-mutant NSCLC.
  • Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said, "Currently, there are many challenges in the treatment of NSCLC.
  • At the ESMO 2023, we presented the latest clinical data that continued to suggest encouraging therapeutic potential of pelcitoclax combined with osimertinib in EGFR-TKI-naïve patients with TP53- and EGFR-mutant NSCLC.
  • In earlier studies, pelcitoclax combined with osimertinib demonstrated clinical potential for the treatment of patients with EGFR-mutant advanced NSCLC resistant to EGFR-TKIs.

PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

Retrieved on: 
Giovedì, Ottobre 12, 2023
Food, September 5, Pharmacokinetics, Female, KRAS, Memorial Sloan Kettering Cancer Center, Vomiting, Breast, AACR, ORR, Chemistry, KOL, TP53, Safety, Mutation, Mass, Endometrial cancer, Nausea, Therapy, RECIST, PMV, Recommender system, Clinical trial, Trae tha Truth, Lung, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neoplasm, Prostate, Conference, Patient, Phase II, Medical imaging, Pharmaceutical industry, Medical device, Birth control, Cancer

Dr. Schram commented, “Patients with a solid tumor harboring a TP53 Y220C mutation are in need of new treatment options, as currently there are no approved therapies targeting p53.

Key Points: 
  • Dr. Schram commented, “Patients with a solid tumor harboring a TP53 Y220C mutation are in need of new treatment options, as currently there are no approved therapies targeting p53.
  • Confirmed responses were observed in patients whose tumors were TP53 Y220C and KRAS wild-type in the efficacious dose range, in multiple tumor types including ovarian, breast, prostate, small-cell lung, and endometrial cancer.
  • The planned Phase 2 patient population includes TP53 Y220C and KRAS wild-type patients.
  • The emerging Phase 1 data have guided us in designing our Phase 2 registrational trial to enroll a TP53 Y220C and KRAS wild-type patient population.

Large-Scale Investigation Supports Modified Classification System for Pulmonary Adenocarcinomas

Retrieved on: 
Lunedì, Settembre 11, 2023
Adenocarcinoma, Ovine pulmonary adenocarcinoma, TP53, Classification, Anxiety, Marie Cassidy, Elastin, International Association, Lung cancer, Research, RFS, Patient, Cancer, Diagnosis, WHO, Health, Recurrence, Conference, World Health Organization, Medical device, Medical imaging

SINGAPORE, Sept. 11, 2023 /PRNewswire-PRWeb/ -- Large-Scale Investigation Supports Modified Classification System for Pulmonary Adenocarcinomas (Singapore – September 11, 2023) – A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.

Key Points: 
  • SINGAPORE, Sept. 11, 2023 /PRNewswire-PRWeb/ -- Large-Scale Investigation Supports Modified Classification System for Pulmonary Adenocarcinomas (Singapore – September 11, 2023) – A modified adenocarcinoma classification approach significantly enhances reproducibility and may be an improvement on the existing World Health Organization classification system, according to research unveiled at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
  • "Our findings suggest that the modified adenocarcinoma classification significantly enhances reproducibility and aligns better with the clinical reality.
  • The objective was to establish a baseline and investigate the potential for an improved classification system, aided by biomarker analysis.
  • Dr. Thunnissen and colleagues conducted a case-control study involving resected adenocarcinomas measuring up to 3 cm (n=70), the research evaluated the potential of a modified classification system.

KRYSTAL-1 Trial Finds that Adagrasib Demonstrates Durable Clinical Activity in Patients with KRAS G12C Mutations

Retrieved on: 
Domenica, Settembre 10, 2023
Docetaxel, KRAS, Hepatotoxicity, TP53, Progression-free survival, IO, Health care, DOR, European Medicines Agency, Survival, International Association, Lung cancer, Hope, Mutation, Medication, Research, NSCLC, Female, CNS, PFS, STK11, EMA, MD, Patient, KEAP1, FDA, Conference, ORR, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, MHRA, Pharmaceutical industry

SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ -- KRAS G12C mutations occur in approximately 14% of patients with NSCLC. The KRYSTAL-1 study, a multicohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS G12C-mutated solid tumors. The U.S. Food and Drug Administration (FDA) granted accelerated approval of adagrasib for patients with previously treated KRAS G12C-mutated advanced/metastatic NSCLC based on data from this study in December 2022. Additionally, the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) are currently reviewing the drug.

Key Points: 
  • SINGAPORE, Sept. 10, 2023 /PRNewswire-PRWeb/ -- KRAS G12C mutations occur in approximately 14% of patients with NSCLC.
  • The KRYSTAL-1 study, a multicohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS G12C-mutated solid tumors.
  • The U.S. Food and Drug Administration (FDA) granted accelerated approval of adagrasib for patients with previously treated KRAS G12C-mutated advanced/metastatic NSCLC based on data from this study in December 2022.
  • The findings suggest durable clinical activity of adagrasib for KRAS G12C-mutated NSCLC.

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Retrieved on: 
Mercoledì, Settembre 6, 2023
TP53, Toronto Stock Exchange, TUS, Hope, Mutation, Consultant, Acute myeloid leukemia, AML, Hanmi Pharmaceutical, Patient, SAN, FLT3, TSX, Safety, Pharmaceutical industry, Security (finance), Hanmi, Share (finance)

Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.

Key Points: 
  • Under the terms of the strategic investment, Hanmi purchased each Share at a price of $4.488, representing a premium over Aptose’s common stock price.
  • Aptose has granted Hanmi certain rights pursuant to an investor rights agreement, including registration rights, pre-emptive rights, information rights and the right to appoint non-executive consultants.
  • The closing of the second tranche for up to $4 million or a maximum of 19.99 percent ownership interest will be triggered upon Aptose achieving, prior to July 1, 2024, certain manufacturing and data milestones related to tuspetinib.
  • “We are grateful to our valued partner Hanmi Pharmaceutical for this investment and their confidence in our strategic direction," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.

iSpecimen Launches New Virtual Cancer Sequencing Procurement Program

Retrieved on: 
Mercoledì, Agosto 30, 2023
NRAS, Tissue, KRAS, National Human Genome Research Institute, TP53, Serum, Breast, Cancer, National Cancer Institute, Brain, Prostate, Lung, Colon, Plasma, The Cancer Genome Atlas, PTEN, EGFR, Risk, Melanoma, DTC, MET, TCGA, RET, ALK, Medical imaging

LEXINGTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, announced today the launch of a new program that gives researchers consistent and direct access to mutation-characterized formalin-fixed, paraffin-embedded (“FFPE”) cancer tumor tissues, relieving a major bottleneck in cancer research. The program will initially offer samples for lung, colon and breast cancers.

Key Points: 
  • The genetic signatures of cancer tumor tissues provide important information necessary to develop new treatments and diagnostics.
  • “This is a very important program for the future of iSpecimen.
  • Our new cancer sequencing procurement program provides cancer researchers with access to mutation-characterized FFPE tumor tissues without requiring that they manage the risk and resource-intense course of overseeing the sequencing process,” said Tracy Curley, iSpecimen’s CEO.
  • As this program progresses, pre-screened samples will be offered for a number of additional cancer types, including pancreatic, renal, brain, ovarian, gastric, melanoma, bladder and prostate.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Martedì, Agosto 22, 2023
Membrane protein, DNA, MDM2, Headache, TP53, Somatic symptom disorder, Survival, NUP107, Enzyme, Cancer, Nuclear envelope, Brain, Cell Reports, Cytoplasm, Protein, Cell nucleus, Cell, Nausea, Diagnosis, Personality, NPC, Genome, Non-player character, Kanazawa University, Vaccine, Glioblastoma

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Kanazawa University research: Brain cancer linked to nuclear pore alterations

Retrieved on: 
Martedì, Agosto 22, 2023
Membrane protein, DNA, MDM2, Headache, TP53, Somatic symptom disorder, Survival, NUP107, Enzyme, Cancer, Nuclear envelope, Brain, Cell Reports, Cytoplasm, Protein, Cell nucleus, Cell, Nausea, Diagnosis, Personality, NPC, Genome, Non-player character, Kanazawa University, Vaccine, Glioblastoma

KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.

Key Points: 
  • KANAZAWA, Japan, Aug. 22, 2023 /PRNewswire/ -- Researchers at Kanazawa University report in Cell Reports how alterations in the nuclear pores lead to the degradation of anti-tumor proteins.
  • Several types of cancer are believed to be linked to alterations of macromolecular structures known as nuclear pore complexes (NPCs).
  • Whether NPC alterations play a role in glioblastoma, the most common type of cancer originating in the brain, is unclear at the moment.
  • Mitsutoshi Nakada and Richard Wong and colleagues first checked whether any nuclear pore complex proteins were amplified ('overexpressed') in glioblastoma.

Aptose Reports Results for the Second Quarter 2023

Retrieved on: 
Giovedì, Agosto 10, 2023
CRC, TP53, Investment, APS, Symantec Endpoint Protection, Toronto Stock Exchange, CRH, Mutation, Hanmi Pharmaceutical, Acute myeloid leukemia, MDS, US, AML, Documentation, Patient, Indian stock exchange, CR, FLT3, CRi, TSX, FDA, CRP, US FDA, Pharmaceutical industry, Security (finance)

Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.

Key Points: 
  • Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.
  • Equity Investments in Aptose – Today, Aptose announced that it has entered into a binding term sheet with Hanmi Pharmaceutical, Inc. (“Hanmi Pharmaceutical”) of Seoul, South Korea, for an investment of up to $7 million or 19.99 percent ownership interest in Aptose, in two tranches.
  • A monotherapy recommended Phase 2 dose of 80 mg daily was selected and all tuspetinib development paths remain open, including the single arm accelerated path.
  • Plan to discuss strategies for potential future monotherapy accelerated development, doublet phase 2 development, and triplet pilot development (4Q 2023)

Shattuck Labs Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Giovedì, Agosto 10, 2023
Mirvetuximab soravtansine, CD47, Completeness, TP53, Macrophage, Neoplasm, American Society of Clinical Oncology, Clinical trial, RECIST, Cancer, Pharmacokinetics, ASCO, AML, Azacitidine, Patient, CD40, Autoimmune disease, Society, Safety, Pharmaceutical industry, PROC

AUSTIN, TX and DURHAM, NC, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended June 30, 2023, and provided recent business highlights.

Key Points: 
  • Initial data from the ongoing Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC expected in the fourth quarter of 2023.
  • Complete dose-escalation data, as monotherapy and in combination with azacitidine, for Phase 1A clinical trial of SL-172154 in primarily relapsed/refractory AML and HR-MDS expected in the fourth quarter of 2023.
  • We expect to complete enrollment for the two expansion cohorts in the fourth quarter of 2023.
  • Subsequently, in the second quarter of 2023, we performed an additional toxicology study in non-human primates that was designed to expand upon the initial non-human primate study.